| Print
Tonix Pharmaceuticals Holding Corp (TNXP)
Common SharesThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
Tonix Pharmaceuticals Holding Corp is a commercial-stage biotechnology company focused on the development and commercialization of treatments for central nervous system (CNS) disorders and immunological conditions. Its product portfolio includes TONMYA (cyclobenzaprine HCl sublingual tablets 2.8 mg), an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as major depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Address
509 Madison Avenue
Suite 306
New York
NY
USA
10022
Telephone
+1 212 980-9155
Forecast key dates
| Name | Key Date |
|---|---|
| Tonix Pharmaceuticals Holding Corp Third Quarter Earnings Results for 2026 | 2026-11-10T00:00:00 |
| Tonix Pharmaceuticals Holding Corp Second Quarter Earnings Results for 2026 | 2026-08-11T00:00:00 |
| Tonix Pharmaceuticals Holding Corp First Quarter Earnings Results for 2026 | 2026-05-12T00:00:00 |
| Tonix Pharmaceuticals Holding Corp Annual General Meeting for 2026 | 2026-05-08T11:00:00 |
| Tonix Pharmaceuticals Holding Corp Fourth Quarter Earnings Results for 2025 | 2026-03-18T16:30:00 |
| Tonix Pharmaceuticals Holding Corp Annual Report for 2025 | 2026-03-18T00:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| Biotech Showcase 2026 | 2026-01-13T11:00:00 |
| Stifel 2025 Healthcare Conference | 2025-11-13T10:00:00 |
| Tonix Pharmaceuticals Holding Corp Third Quarter Earnings Results for 2025 | 2025-11-10T00:00:00 |
| Cantor Global Healthcare Conference 2025 | 2025-09-04T13:35:00 |
| Tonix Pharmaceuticals Discussion of Tonmya™ Approval | 2025-08-18T08:30:00 |
| Tonix Pharmaceuticals Holding Corp Second Quarter Earnings Results for 2025 | 2025-08-11T00:00:00 |
| Tonix Pharmaceuticals Holding Corp First Quarter Earnings Results for 2025 | 2025-05-12T00:00:00 |
| Tonix Pharmaceuticals Holding Corp Annual General Meeting for 2025 | 2025-05-08T11:00:00 |
| 2025 Jones Trading Healthcare and Innovation Conference | 2025-04-09T10:00:00 |
| Tonix Pharmaceuticals Holding Corp Fourth Quarter Earnings Results for 2024 | 2025-03-18T16:30:00 |
| Tonix Pharmaceuticals Holding Corp Annual Report for 2024 | 2025-03-18T00:00:00 |
| Zacks SCR Life Sciences Virtual Investor Forum | 2025-03-13T15:30:00 |
| 2025 Virtual Investor Summit | 2025-03-11T10:30:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2026 AJ Bell. All rights reserved.